No record found


* Returns not adjusted for payouts
Company Profile
Abbott Laboratories (Pakistan) Limited is a public limited company incorporated in Pakistan on July 02, 1948. The Company is principally engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products.
Mr. Syed Anis Ahmed | CEO |
Mr. Ehsan Ali Malik | Chairman |
Company Secretary |
Plot No. 258 & 324, Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi, Pakistan
FAMCO Associates (Pvt) Limited, 8-F, Next to Hotel Faran, Nursery Block 6, P.E.C.H.S, Shahrah-e-Faisal,Karachi
EY Ford Rhodes, Chartered Accountants
December
Equity Profile
Announcements
Date | Title | Document |
---|---|---|
May 6, 2022 | Transmission of Quarterly Report for the Period Ended March 31, 2022 | View PDF |
Apr 28, 2022 | Financial Results for the Quarter ended March 31, 2022 | View PDF |
Mar 29, 2022 | Transmission of Annual Report for the Year Ended December 31, 2021 | View PDF |
Mar 24, 2022 | Transmission of Annual Report for the Year Ended December 31, 2021 REVOKED | View PDF |
Feb 24, 2022 | Financial Results for the Year Ended December 31, 2021 | View PDF |
Oct 29, 2021 | Transmission of Quarterly Report for the Period Ended September 30, 2021 | View PDF |
Oct 27, 2021 | Financial Results for the Quarter Ended September 30, 2021 | View PDF |
Aug 27, 2021 | Transmission of Quarterly Report for the Period Ended June 30, 2021 | View PDF |
Aug 27, 2021 | Financial Results for the Quarter Ended June 30, 2021 | View PDF |
Apr 30, 2021 | Transmission of Quarterly Report for the Period Ended March 31, 2021 | View PDF |
Apr 23, 2021 | Financial Results for the 1st Quarter Ended March 31, 2021 | View PDF |
Mar 31, 2021 | Transmission of Annual Report for the Year Ended December 31st, 2020 | View PDF |
Date | Title | Document |
---|---|---|
Apr 21, 2022 | Board Meeting | View PDF |
Mar 29, 2022 | Notice of Annual General Meeting | View PDF |
Feb 17, 2022 | Board Meeting | View PDF |
Oct 21, 2021 | Board Meeting | View PDF |
Aug 17, 2021 | Board Meeting | View PDF |
Apr 22, 2021 | Certified Copy of Resolution passed at the 72nd Annual General Meeting | View PDF |
Apr 16, 2021 | Board Meeting | View |
Apr 6, 2021 | Board Meeting Other Than Financial Results | View PDF |
Mar 29, 2021 | Notice of Annual General Meeting | View PDF |
Feb 15, 2021 | Board Meeting | View PDF |
Oct 20, 2020 | Board Meeting | View |
Date | Title | Document |
---|---|---|
May 24, 2022 | Resignation of Company Secretary | View PDF |
May 9, 2022 | Credit of Final Cash Dividend | View PDF |
May 6, 2022 | Change of Chairman | View PDF |
Mar 24, 2022 | Miscellaneous Information | View PDF |
Dec 10, 2021 | Notice for Corporate Briefing Session | View PDF |
Sep 23, 2021 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Sep 22, 2021 | Dispatch of Interim Cash Dividend | View PDF |
Jun 4, 2021 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
May 4, 2021 | Credit of Final Cash Dividend | View |
May 4, 2021 | Credit of Final Cash Dividend REVOKED | View |
Mar 8, 2021 | Unusual Movement in price or volume of M/s Abbott Laboratories (Pakistan) Limited (ABOT) | View |
Mar 8, 2021 | ABOT | Abbott Laboratories (Pakistan) Limited | |
Dec 18, 2020 | Information under regulation No. 5.6.1(d) of PSX Rule Book | View PDF |
Financials
All numbers in thousands (000's) except EPS
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Sales | 42,569,856 | 35,283,377 | 30,155,875 | 29,719,279 |
Profit after Taxation | 5,967,057 | 4,535,249 | 1,299,885 | 2,694,333 |
EPS | 60.95 | 46.33 | 13.28 | 27.52 |
Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | |
---|---|---|---|---|
Sales | 11,771,159 | 10,649,306 | 10,907,191 | 9,890,792 |
Profit after Taxation | 1,441,779 | 1,209,913 | 1,839,497 | 1,442,492 |
EPS | 14.73 | 12.36 | 18.79 | 14.73 |

Ratios
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Gross Profit Margin (%) | 37.76 | 34.64 | 28.28 | 32.89 |
Net Profit Margin (%) | 14.02 | 12.85 | 4.31 | 9.07 |
EPS Growth (%) | 31.56 | 248.87 | (51.74) | (35.93) |
PEG | 0.37 | 0.07 | (0.66) | (0.64) |
Payouts
Date | Financial Results | Details | Book Closure |
---|---|---|---|
February 24, 2022 2:57 PM | 31/12/2021(YR) | 200%(F) (D) | 14/04/2022 - 21/04/2022 |
August 27, 2021 11:10 AM | 30/06/2021(YR) | 200%(i) (D) | 10/09/2021 - 17/09/2021 |
February 26, 2021 4:27 PM | 31/12/2020(YR) | 250%(F) (D) | 14/04/2021 - 21/04/2021 |
August 28, 2020 12:14 PM | 30/06/2020(HYR) | 150% (i) (D) | 09/09/2020 - 16/09/2020 |
March 2, 2020 3:11 PM | 31/12/2019(YR) | 75%(F) (D) | 20/05/2020 - 27/05/2020 |
February 21, 2019 3:04 PM | 31/12/2018(YR) | 100%(F) (D) | 16/04/2019 - 23/04/2019 |
August 17, 2018 3:07 PM | 30/06/2018(HYR) | 100% (D) | 04/09/2018 - 11/09/2018 |
February 26, 2018 3:36 PM | 31/12/2017(YR) | 300% (D) | 14/04/2018 - 23/04/2018 |
August 21, 2017 3:09 PM | 30/06/2017(HYR) | 100% (D) | 08/09/2017 - 15/09/2017 |
February 27, 2017 5:03 PM | 31/12/2016(YR) | 300% (D) | 11/04/2017 - 18/04/2017 |